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Abstract: A quantitative structure–activity relationship analysis was employed to explore the relationship between the 
molecular structure of thiosemicarbazone analogues and the inhibition of the cysteine protease cruzain, a validated target 
for Chagas’ disease treatment. A data set containing 53 thiosemicarbazone derivatives was used to produce a quantitative 
model for activity prediction of unknown compounds. Several electronic descriptors were obtained through DFT calcula-
tions, along with a large amount of Dragon descriptors. The ordered predictor selection (OPS) algorithm was employed to 
select the most relevant descriptors to perform PLS regressions. With this procedure, significant correlation coefficients 
(r2 = 0.85, q2 = 0.78) were achieved. Furthermore, predicted values for an external test set are in good agreement with the 
experimental results, indicating the potential of the model for untested compounds. Additional validation tests were car-
ried out, indicating that a robust and reliable model was obtained to be used in the design of new thiosemicarbazones with 
improved cruzain inhibition potential. 
Keywords: Chagas’ disease, Cysteine protease cruzain, Thiosemicarbazones, Molecular modeling, Quantum chemical meth-
ods, DFT, OPS-PLS studies, Drug design. 
1. INTRODUCTION
Parasitic diseases represent an urgent medical issue since 
they affect hundreds of millions of people around the world. 
Nevertheless, most of the drugs targeting these diseases are 
of limited efficacy, present severe side effects and drug resis-
tance [1,2]. Despite the recent increase in supporting the 
development and drug discovery by public-private partner-
ships and philanthropic funding, the development of new 
drugs have not been meeting expectations [3,4]. 
Chagas’ disease is one of the most deadly parasitic dis-
eases, affecting 16 to 18 million people. Long treatments and 
adverse effects limit the patient compliance to the commonly 
used drugs, nifurtimox and benznidazole, which are also 
ineffective in late-stage of the disease. Safe orally bioavail-
able drugs, especially for the chronic phases of disease, are 
the main therapy needs for fighting Chagas’ disease [1,2,5].  
The advances in the knowledge of parasite genome 
sequences offer good opportunities for drug discovery based 
on the identification and validation of new molecular drug 
targets. Among the most attractive targets from Trypano 
*Address correspondence to this author at the Instituto de Química de São
Carlos - USP, São Carlos, SP, Brazil; Tel: 55-16-33739964; Fax: 55-16-
33739975; E-mail: alberico@iqsc.usp.br 
soma cruzi, the parasite causing Chagas’ disease, the cys-
teine protease cruzain is involved in the main stages of host 
cell infection, as well as parasite replication and differentia-
tion [6-9]. Cruzain inhibitors have been shown to be one of 
the most promising classes of antitrypanosomal agents. A 
remarkable example is the compound WRR-483, an analog 
of vinyl sulfone K777, which showed unexpected activity 
against parasite cultures and animal models [9,10]. Other 
compounds that have intensively been studied as cruzain 
inhibitors are chalcone and acylhydrazide derivatives, along 
with pyrimidines [11,12]. 
Thiosemicarbazones are a promising class of small mole-
cules that have been evaluated against Trypanosoma cruzi, 
Trypanosoma brucei, Plasmodium falciparum, and various 
other parasites [13-15] (see Fig. 1a). The effectiveness of 
thiosemicarbazone analogues in treating these diseases is 
reported due to their activity against cysteine proteases in-
cluding cruzain [16]. Du and coworkers [17] have identified 
the thiosemicarbazone compounds as potent inhibitors of 
trypanosomal infection. In particular, the 3-bromopropio-
phenone thiosemicarbazone derivative 5 (see Fig. 1b) is an 
effective cruzain inhibitor that demonstrates trypanocidal 
activity at concentrations that exhibit no toxicity for mam-
malian cells.  
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Fig. (1). (a) Thiosemicarbazone general structure and (b) the structure of thiosemicarbazone derivative 5, as an example.
These compounds have presented suitable pharmacoki-
netics (low molecular weight, favorable C log P, favorable 
hydrogen bond donating and accepting capabilities), and low 
cost synthesis [17]. Quantitative structure–activity relation-
ship (QSAR) studies, along with the available X-ray crystal-
lographic cruzain–inhibitor complexes, have shown to be 
useful tools in the lead compound optimization as potential 
therapeutic agents for the treatment of Chagas’ disease and 
in understanding the role of cruzain in the pathology [18-22].  
In order to provide useful insights for further structural 
optimization of this class of compounds, in the present work 
we have employed an useful protocol [23-29], in which we 
have performed the calculation of a large amount of elec-
tronic, structural and topological descriptors to be employed 
in a PLS analysis, aiming at the construction of a predictive 
model of the quantitative structure-activity relationships for 
the cruzain inhibition presented by the compounds studied 
here. Model interpretation and analysis of molecular orbitals 
are discussed in terms of the influence of the molecular orbi-
tals on the design of new antitrypanosomal chemotherapeutic 
agents. 
2. METHODOLOGY
2.1. Data Set 
A series of 53 thiosemicarbazones and semicarbazones 
acting as cruzain inhibitors was selected from the literature 
[17]. The IC50 values, measured under the same experimental 
conditions, were converted to the corresponding pIC50
(-logIC50) to be used as dependent variable in the multivari-
ate analyses. Structures and pIC50 values for training and test 
set compounds are listed in Table 1. The Kennard-Stone al-
gorithm [30] was employed to split the full data set into 
training (40 compounds) and test (13 compounds) sets. A 
Hierarchal Cluster Analysis (HCA) on the samples was also 
undertaken in order to assure that the structural diversity and 
the IC50 distribution of the data set were well represented in 
both training and test sets. Fig. (2) shows that pIC50 values 
for training and test sets are properly distributed in both sets 
(spanning three orders of magnitude). 
2.2. Descriptor Calculation and Selection 
The structures of all compounds were initially optimized 
with the semiempirical method PM3 [31]. A re-optimization 
was performed with the density functional theory (DFT) us-
ing the B3LYP functional [32] and 14 electronic descriptors 
were calculated using Gaussian 09 [33]. A set of 1209 
Dragon descriptors [34], encoding useful information about 
several aspects of molecular structure, were also calculated. 
All descriptors were autoscaled so that they have the same 
weight. 
With the aim to reduce the number of descriptors, the ab-
solute values of correlation coefficients between each de-
scriptor and pIC50 were calculated. Descriptors with coeffi-
cients lower than 0.3 were excluded from the analysis. Addi-
tionally, descriptors presenting a non-uniform distribution 
with the pIC50 were also eliminated. This procedure reduced 
the initial set to 17 descriptors. Subsequently, the Ordered 
Predictor Selection (OPS) algorithm [35] was employed to 
perform a variable selection. The basic idea of this algorithm 
is to attribute an importance to each descriptor based on an 
informative vector. The columns of the matrix are rearranged 
in such a way that the most important descriptors are pre-
sented in the first columns. Then, successive PLS regressions 
are performed with an increasing number of descriptors in 
order to find the best PLS model. In this analysis, the regres-
sion vector was used as an informative vector and the corre-
lation coefficient of crossvalidation, q2, as a criterion to se-
lect the best models.  
The optimum number of latent variables was chosen as 
the one presenting the lowest values of PRESS (prediction 
residues error squares sum) and SEV (standard error of vali-
dation). The quality of the PLS model obtained was evalu-
ated by the cross-validation (leave-one-out) and calibration 
coefficients q2 and r2, respectively, and by the prediction 
residues obtained from external validation (test set). This 
model was additionally validated applying leave-N-out 
(LNO) cross-validation and y-randomization tests. In the 
LNO cross-validation procedure, N compounds (N varying 
from 1 to 13) were left out from the training set. For a par-
ticular N, the data were randomized 30 times, and the aver-
age and standard deviation values for q2 were used. In the y-
randomization, the dependent variable-vector was scrambled 
50 times in order to verify the occurrence of chance correla-
tion between the dependent variable and the selected descrip-
tors [36,37]. 
3. RESULTS AND DISCUSSION
3.1. Statistical Results 
By using the OPS variable selection algorithm, 8 
descriptors were selected: , X1A, BELm3, JGI2, MATS2m,  
Antitrypanosomal Activity of Thiosemicarbazones and OPS-PLS QSAR Studies Medicinal Chemistry, 2012, Vol. 8, No. 6    1047
Table 1. Chemical Structures and pIC50 Values for Training and Test Set Compounds [18] 
Cpd R1 R2 R3 X pIC50 Cpd R
1 R2 R3 X pIC50
N
R2
N
X
N
R3
R1
H
General structure 
Training set 
1
CH3
ClCl
H H S 7.70 21
Br
H H S 5.89
2
CH3
CF3
F3C
H H S 7.70 22
Br
(CH2)5CH3 S 5.85
3
H3C
CF3
H S 7.40 23
Br
H CF3 S 5.80 
4
CH3
F3C
H H S 7.30 24
Cl
CF3
S 5.77 
5
H3C
Cl Cl
H H S 7.30 25 S
Cl
H H S 5.72
6
H3C
CF3
F3C
H H S 7.22 26
N
S
O
O
H H S 5.55
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Table 1. contd… 
Cpd R1 R2 R3 X pIC50 Cpd R
1 R2 R3 X pIC50
7
Cl
Cl
H S 7.15 27 S
Br
H H S 5.42
8
Br
H S 7.10 28
Br
H H S 5.41
9
O
Cl H H S 6.85 29
F3C
H H S 5.00
10
H3C
F3C
H H S 6.77 30
Br
H (CH3)2 S 5.00
11
H3C
Br
H H S 6.70 31 CH3 S 5.00
12
Br
H S 6.70 32
Br
(CH3)2 S 5.00
13
Cl
CH3
H H S 6.66 33
Cl
Cl
H H O 5.00
14
Cl
H S 6.64 34
Br
H H O 5.00
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Table 1. contd… 
Cpd R1 R2 R3 X pIC50 Cpd R
1 R2 R3 X pIC50
15
O
Cl
H H S 6.52 35
O
Cl
H H O 5.00 
16 F3C
CF3
H H S 6.49 36
O
Br
H H O 5.00 
17
ClCl
H H S 6.34 37
Br
H S 5.00 
18
F3C
H H S 6.32 38
O
Cl H H O 5.00 
19 Cl
Cl
H H S 6.25 39 HO
OH3C
H H S 5.00 
20
Br
Cl
S 6.00 40
NH3C
CH3
H H S 5.00 
Test set
41
Cl
Cl
H S 7.22 48 N H H S 5.55 
42
CF3
H S 7.10 49
S
N
N
F3C
H H S 5.15 
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Table 1. contd… 
Cpd R1 R2 R3 X pIC50 Cpd R
1 R2 R3 X pIC50
43
Br
H H S 7.00 50 
O
H3C
H H S 5.00 
44
Cl
H S 6.57 51 H CH3 S 5.00 
45
OO
H3C
H H S 6.55 52 
Br
H CH2CH3 S 5.00 
46
O
Br
H H S 6.55 53 
Cl
Cl
H H O 5.00 
47
O
CH3
H H S 6.25       
Fig. (2). Distribution of pIC50 values for training and test set compounds. 
RDF010m, Mor12v, and H7m (see Table 2 for the descrip-
tion of each one). The values calculated for the 8 selected 
descriptors are shown in Table 3.
The PLS regression model obtained with these descrip-
tors resulted in the statistical parameters presented in Table 
4.  The  optimum  number  of  latent  variables  was  5,  since  
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Table 2. Symbols, Types and Definitions of Selected Descriptors 
Descriptor Type Definition 
 Electronic Dipole moment 
X1A Topological Average connectivity index 1 [38] 
BELm3 BCUT Lowest eigenvalue n.3 of Burden matrix/weighted by atomic masses [39] 
JGI2 Galvez topological charge 
indices 
Mean topological charge index of order 2 [40] 
MATS2m 2D autocorrelations Moran autocorrelation – lag 2/ weighted by atomic masses [41] 
RDF010m RDF Radial distribution function – 1.0/ weighted by atomic masses [42] 
Mor12v 3D-MoRSE 3D-MoRSE – signal 12/ weighted by atomic van der Waals volumes [43,44] 
H7m GETAWAY H autocorrelation of lag 2/ weighted by atomic masses [45,46] 
Table 3. Values of the 8 Selected Descriptors for Training and Test Set Compounds 
Compound   (D) X1A BELm3 JGI2 MATS2m RDF010m Mor12v H7m 
Training Set
1 8.159 0.471 1.329 0.148 0.991 0.589 0.051 0.137 
2 2.024 0.452 1.336 0.159 0.987 0.592 -0.149 0.189 
3 5.521 0.439 1.387 0.160 0.978 0.570 -0.176 0.303 
4 6.367 0.463 1.335 0.144 0.980 0.634 -0.188 0.349 
5 10.170 0.467 1.289 0.159 0.993 0.521 0.088 0.136 
6 9.541 0.448 1.289 0.167 0.988 0.521 -0.052 0.103 
7 3.806 0.444 1.374 0.167 0.990 0.532 -0.041 0.013 
8 4.732 0.446 1.382 0.133 0.984 0.577 0.018 0.048 
9 7.000 0.455 1.390 0.092 0.978 0.592 0.327 0.161 
10 3.321 0.459 1.289 0.153 0.981 0.568 -0.071 0.062 
11 4.245 0.471 1.289 0.120 0.987 0.568 0.140 0.000 
12 5.466 0.448 1.349 0.127 0.987 0.508 0.188 0.008 
13 6.304 0.475 1.333 0.111 0.981 0.634 0.001 0.140 
14 9.824 0.446 1.383 0.133 0.979 0.570 -0.051 0.152 
15 4.756 0.455 1.381 0.105 0.978 0.592 0.292 0.151 
16 8.637 0.450 1.203 0.140 0.987 0.453 0.020 0.022 
17 9.405 0.471 1.169 0.120 0.991 0.446 0.298 0.109 
18 5.228 0.462 1.202 0.119 0.979 0.497 0.096 0.166 
19 7.702 0.470 1.171 0.068 0.991 0.453 0.384 0.109 
20 6.348 0.442 1.616 0.106 0.986 0.595 0.432 0.006 
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Table 3. contd… 
Compound   (D) X1A BELm3 JGI2 MATS2m RDF010m Mor12v H7m 
21 5.440 0.476 1.193 0.074 0.985 0.497 0.414 0.012 
22 4.376 0.464 1.672 0.100 0.972 0.813 -0.294 0.003 
23 1.150 0.454 1.681 0.130 0.983 0.720 0.136 0.034 
24 3.593 0.438 1.618 0.130 0.981 0.595 0.368 0.286 
25 6.587 0.469 1.289 0.130 0.987 0.477 0.083 0.088 
26 12.350 0.453 1.480 0.152 0.966 0.681 0.180 0.171 
27 4.370 0.469 1.289 0.130 0.992 0.479 0.142 0.007 
28 7.492 0.472 1.289 0.137 0.987 0.558 0.222 0.002 
29 3.066 0.463 1.199 0.133 0.979 0.503 0.184 0.125 
30 3.482 0.473 1.651 0.139 0.982 0.647 -0.205 0.047 
31 4.902 0.453 1.540 0.133 0.985 0.524 0.301 0.003 
32 8.223 0.449 1.593 0.139 0.983 0.513 0.383 0.108 
33 0.180 0.471 1.382 0.148 0.987 0.588 0.113 0.045 
34 2.382 0.471 1.346 0.120 0.982 0.564 0.201 0.000 
35 4.395 0.455 1.407 0.105 0.974 0.596 0.347 0.058 
36 3.465 0.455 1.405 0.105 0.978 0.596 0.412 0.031 
37 5.065 0.463 1.681 0.089 0.976 0.738 0.510 0.003 
38 3.871 0.455 1.390 0.092 0.978 0.592 0.291 0.044 
39 8.459 0.455 1.577 0.123 0.965 0.777 0.081 0.034 
40 8.702 0.475 1.360 0.111 0.972 0.654 0.212 0.046 
Test Set
41 10.130 0.446 1.329 0.163 0.993 0.451 0.139 0.148 
42 5.400 0.441 1.359 0.157 0.980 0.508 -0.031 0.025 
43 5.892 0.475 1.333 0.111 0.985 0.624 -0.048 0.028 
44 9.813 0.448 1.350 0.127 0.981 0.496 0.060 0.100 
45 6.482 0.460 1.436 0.099 0.970 0.685 0.244 0.113 
46 4.880 0.455 1.378 0.105 0.982 0.586 0.357 0.151 
47 8.051 0.459 1.414 0.118 0.968 0.671 0.209 0.015 
48 8.492 0.452 1.429 0.119 0.967 0.620 0.176 0.091 
49 4.601 0.444 1.499 0.133 0.980 0.565 0.334 0.171 
50 6.743 0.475 1.424 0.111 0.973 0.658 0.027 0.006 
51 3.897 0.479 1.558 0.119 0.983 0.651 0.115 0.091 
52 3.919 0.480 1.678 0.111 0.981 0.701 0.075 0.090 
53 0.508 0.467 1.345 0.159 0.989 0.526 0.176 0.000 
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those were the ones presenting the lowest PRESS and SEV 
values. For the best model, correlation coefficients are 
q2=0.78 and r2=0.85, indicating good internal consistency. 
The contributions of each descriptor to the regression vector 
for the best model obtained are displayed in Fig. (3). 
Table 4. Statistical Parameters for the PLS Regressions Using 
the 8 Selected Descriptors 
Factors SEV PRESS q2 r2
1 0.64 16.59 0.48 0.55
2 0.56 12.35 0.62 0.77
3 0.46 8.46 0.74 0.81
4 0.42 7.15 0.78 0.83
5 0.42 7.09 0.78 0.85
6 0.43 7.25 0.78 0.85
7 0.42 7.18 0.78 0.85
8 0.44 7.70 0.76 0.85
3.2. Model Validation 
The predictive power of the PLS model was evaluated by 
predicting the biological activity of the compounds from the 
test set (external validation). Experimental and predicted 
pIC50 values are listed in Table 5. A plot of experimental 
versus predicted pIC50 values comparing the compounds in 
both training and test sets is shown in Fig. (4). The good 
agreement between the experimental and calculated values 
indicates that a predictive PLS model was obtained and can 
be used to accurately predict the biological activity of other 
compounds within this structural class. 
In order to evaluate the robustness and stability of the 
PLS model obtained, leave-N-out and y-randomization tests 
were carried out. In fact, a good QSAR model must have an 
average value of q2 close to the cross-validation q2 obtained 
with the leave-one-out procedure, while the standard devia-
tion for each N should not exceed 0.1. It is recommended 
that N represents at least 30% of the samples. Our PLS 
model is stable for until N=10, with deviations from q2 for 
each N being lower than 0.062. These findings indicate the 
stability and robustness of our PLS model (see Fig. 5a). 
Chance correlation between the dependent variable and 
to the selected descriptors was verified employing the y-
Fig. (3). Contributions of each descriptor to the regression vector. 
Table 5. Experimental and Predicted pIC50 Values for the Test Set Compounds 
Compound Experimental pIC50 Predicted pIC50 Residual 
41 7.22 7.23 -0.01
42 7.10 5.91 1.19
43 7.00 6.61 0.39
44 6.57 6.28 0.29
45 6.55 5.57 0.98
46 6.55 6.34 0.21
47 6.25 5.05 1.20
48 5.55 4.99 0.56
49 5.15 5.67 -0.52
50 5.00 4.93 0.07
51 5.00 5.07 -0.07
52 5.00 4.83 0.17
53 5.00 5.22 -0.22
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randomization validation. In this test, the pIC50 values are 
scrambled and the r2 and q2 values are calculated. If low val-
ues for both parameters are found, then one can be sure that a 
true correlation of the descriptors with the response variable 
exists in the data set [36,37]. In the 50 y-randomizations per-
formed for our data, only low values of r2 and q2 were ob-
tained. In the cases where q2 is high, the corresponding r2 is 
extremely low, as can be seen in Fig. (5b). So, this indicates 
that the descriptors selected by the OPS algorithm possess a 
true correlation with the dependent variable, indicating that 
our statistical results are not the result of chance correlation. 
3.3. Model Interpretation 
Regarding the selected descriptors used to build the 
QSAR model presented in this study, some considerations 
can be pointed out. The dipole moment is an electronic de-
scriptor that represents the behavior of a molecule in an elec-
trostatic field. Dipole properties have been correlated to long 
range ligand-receptor recognition and subsequent binding 
between the ligand and receptor [47]. The conformation in-
dependent index X1A is a topological descriptor that repre-
sents the average connectivity of the atoms in the molecule 
[38]. BELm3 is also a 2D descriptor from the class of BCUT 
Fig. (4). Experimental versus predicted pIC50 values of the training and test set compounds. 
(a) (b) 
Fig. (5). Plots of the results for (a) leave-N-out and (b) y-randomization tests. 
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descriptors, which accounts for the first eight lowest absolute 
eigenvalues for the modified Burden adjacency matrix, 
where m refers to the atomic property (atomic masses in this 
case) and 3 is the eigenvalue rank [39]. JGI2 belongs to 
GALVEZ class descriptors, which are the Galvez topological 
charge indices, and have their origin in the first 10 eigenval-
ues of the polynomial of corrected adjacency matrix of the 
compounds [40]. JGIn represents the mean topological 
charge index of order n (JGIn). The ordered sequence of the 
lowest eigenvalues reflects the relevant aspects of molecular 
structure, which are useful for similarity searching [39,40]. 
The positive regression coefficient of descriptors  and JGI2 
means that a higher value of them is beneficial to cruzain 
inhibition, while lower values for X1A and BELm3 are ex-
pected to this purpose. 
MATS2m is a Moran’s 2D autocorrelation descriptor that 
indicates whether the value of an atomic property at one 
atom in the molecular structure is independent of the values 
of the property at neighboring atoms [41]. The computation 
of this class of descriptors involves the summations of dif-
ferent autocorrelation functions corresponding to the differ-
ent fragment lengths and lead to different autocorrelation 
vectors corresponding to the lengths of the structural frag-
ments. Also, a weighting component in terms of a physico-
chemical property (atomic mass, in this case) is encoded in 
this descriptor [41]. Therefore, this descriptor addresses the 
topology of the structure or parts thereof in association with 
a selected physicochemical property. On the other hand, the 
selection of the 3D descriptors Mor12v and RDF010m can 
be related to the importance of molecular conformation of 
thiosemicarbazone analogues for the interaction with key 
amino acids from the binding site of cruzain [42-44]. It is 
evident, from the signs of regression coefficients of Mor12v 
and MATS2m, that these descriptors contribute negatively to 
the activity. Thus, lower values for Mor12v and MATS2m 
are required, while higher RDF010m values are expected to 
increase the activity of the compounds under study. 
GETAWAY (Geometry, Topology and Atom-Weight 
AssemblY) descriptors try to match 3D-molecular geometry 
provided by the molecular influence matrix and molecular 
topology with chemical information by using different 
atomic weightings (atomic mass, polarizability, van der 
Waals volume, and electronegativity) [45,46]. The informa-
tion provided by the H7m descriptor in our PLS model is 
weighted by atomic masses, having a positive influence on 
the biological activity [45,46]. It is interesting to notice that 
four descriptors weighted by atomic masses (BELm3, 
MATS2m, RDF010m, H7m) were selected to compose our 
PLS model. This suggests that the interaction of thiosemi-
carbazone derivatives with cruzain can also depend on the 
distribution of atomic masses along the topological structure 
of these compounds. 
4. CONCLUSIONS
Thiosemicarbazones are potent antitrypanosomal ligands 
presenting advantages over others, since they have possible 
synthetic achievement and a desirable pharmacokinetic pro-
file. The development of QSAR models has been proved to 
play an important role in the discovery and optimization of 
promising drug candidates. The QSAR strategy employed in 
this work has provided a reliable model for cruzain inhibi-
tion within the class of ligands studied. Our findings suggest 
the importance of electronic, topological, 2D autocorrelation 
and 3D features for the antichagasic activity optimization. 
The descriptors identified within the OPS-PLS approach 
have highlighted the role of molecular features accounting 
for electronic effects described by dipole moment and topo-
logical charges. Additionally, the influence of atomic masses 
is indicated by Moran and GETAWAY descriptors, as well 
as by BCUT and radial distribution function descriptors. 
Indeed, the biological activities presented by these com-
pounds are not conformation-independent since 3D-MoRSE 
and RDF descriptors were selected, along with the dipole 
moment which also reflects molecular geometry. These re-
sults can be used to design other thiosemicarbazone deriva-
tives with higher antitrypanosomal activity. 
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